We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-5.38%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$530M
AUM Growth
+$88.9M
Cap. Flow
+$121M
Cap. Flow %
22.77%
Top 10 Hldgs %
58.16%
Holding
331
New
70
Increased
91
Reduced
51
Closed
65

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$32.3M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$24M
3
BBIO icon
BridgeBio Pharma
BBIO
+$19.5M
4
ROIV icon
Roivant Sciences
ROIV
+$14.9M
5
RPRX icon
Royalty Pharma
RPRX
+$12.8M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.1M
2
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$13.3M
3
EDR
Endeavor Group Holdings, Inc.
EDR
+$3.85M
4
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$3.78M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 80.42%
2 Financials 1.75%
3 Industrials 0.22%
4 Utilities 0.17%
5 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
51
DELISTED
Merus
MRUS
$1.59M 0.3%
+26,850
New +$1.3M
ONC
52
BeOne Medicines Ltd
ONC
$33.5B
$1.58M 0.3%
11,100
-20,405
-65% -$3.14M
AURA icon
53
Aura Biosciences
AURA
$740M
$1.54M 0.29%
+203,237
New +$1.49M
KYMR icon
54
Kymera Therapeutics
KYMR
$8.59B
$1.51M 0.29%
50,626
+34,626
+216% +$1.2M
APLT
55
DELISTED
Applied Therapeutics
APLT
$1.5M 0.28%
320,727
-135,861
-30% -$643K
QQQ icon
56
PUT
Invesco QQQ Trust
QQQ
$485B
$1.44M 0.27%
3,000
-7,000
-70% -$3.15M
CNTX icon
57
Context Therapeutics
CNTX
$57.1M
$1.29M 0.24%
645,161
+439,227
+213% +$757K
ATXS
58
DELISTED
Astria Therapeutics
ATXS
$1.26M 0.24%
138,158
+133,506
+2,870% +$1.3M
IBIO icon
59
iBio
IBIO
$72.5M
$1.2M 0.23%
570,000
-30,000
-5% -$64.5K
SPRO icon
60
Spero Therapeutics
SPRO
$71.2M
$1.19M 0.23%
918,929
-8,000
-0.9% -$12.1K
INDV icon
61
Indivior Pharmaceuticals
INDV
$4.31B
$1.13M 0.21%
70,007
+42,406
+154% +$765K
PFE icon
62
Pfizer
PFE
$145B
$1.12M 0.21%
39,950
-66,392
-62% -$1.83M
NVNO
63
enVVeno Medical
NVNO
$7.44M
$1.06M 0.2%
5,764
– –
TH icon
64
Target Hospitality
TH
$1.59B
$990K 0.19%
+113,626
New +$1.19M
GH icon
65
Guardant Health
GH
$21.4B
$982K 0.19%
34,000
+17,000
+100% +$396K
VIR icon
66
Vir Biotechnology
VIR
$1.55B
$979K 0.18%
+110,000
New +$1.05M
CGEM icon
67
Cullinan Oncology
CGEM
$1.08B
$929K 0.18%
+53,261
New +$1.13M
PCVX icon
68
Vaxcyte
PCVX
$7.9B
$925K 0.17%
12,250
+10,250
+513% +$698K
ITOS
69
DELISTED
iTeos Therapeutics
ITOS
$890K 0.17%
+60,000
New +$860K
ALEC icon
70
Alector
ALEC
$171M
$887K 0.17%
195,311
+142,811
+272% +$735K
DNLI icon
71
Denali Therapeutics
DNLI
$3.84B
$882K 0.17%
38,000
+36,000
+1,800% +$691K
ANGO icon
72
AngioDynamics
ANGO
$628M
$870K 0.16%
143,862
-9,500
-6% -$58.6K
ARVN icon
73
Arvinas
ARVN
$581M
$862K 0.16%
32,400
+6,200
+24% +$198K
SYRE icon
74
Spyre Therapeutics
SYRE
$9.11B
$827K 0.16%
35,180
-14,320
-29% -$483K
AGR
75
DELISTED
Avangrid, Inc.
AGR
$817K 0.15%
+23,000
New +$830K
1 2
3
4 5

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

ADAR1 Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, ADAR1 Capital Management held 331 positions worth $530M, up 20% from $441M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

ADAR1 Capital Management deployed $121M of net new capital in Q2 2024, opening 70 new positions and adding to 91 existing holdings. Its largest new stake was Perceptive Capital Solutions: 750,000 shares worth $7.54M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 69% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $28.1M trimmed.

  • ADAR1 Capital Management's largest Q2 2024 buy was Perceptive Capital Solutions: 750,000 shares worth $7.54M.
  • ADAR1 Capital Management added most to Cytokinetics in Q2 2024, an estimated $32.3M increase.
  • ADAR1 Capital Management's biggest Q2 2024 reduction was Alnylam Pharmaceuticals, cutting an estimated $28.1M.
  • ADAR1 Capital Management fully exited Merrimack Pharmaceuticals, Inc. in Q2 2024, selling an estimated $13.3M.
  • ADAR1 Capital Management's ten largest holdings make up 58% of its $530M portfolio in Q2 2024.
  • ADAR1 Capital Management opened 70 new positions and closed 65 in Q2 2024.
  • ADAR1 Capital Management's portfolio value rose 20% quarter-over-quarter to $530M.

Based on ADAR1 Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.